NCT06631066

Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 160 (actual)
• Sponsor: National Cancer Institute, Egypt · Academic / Other
• Sex: Female
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a phase II randomized trial comparing pathologic complete response rates in locally advanced patients recieving either neoadjuvant chemotherapy or neoadjuvant chemoradiation.

Detailed description

A prospective randomized phase II trial, that enrolled locally advanced breast cancer patients who were randomized to recieve either neoadjuvant systemic treatment or neoadjuvant systemic treatment concurrently with radiotherapy. Surgery is done for all patients later on as indicated. The pathological response rates between both groups will be compared, as well as surgical complications and acute radiation toxicity.

Conditions

• Breast Cancer Female

Interventions

Type	Name	Description
RADIATION	neoadjuvant chemoradiation	Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.

Timeline

• Start date: 2021-10-20
• Primary completion: 2023-10-10
• Completion: 2024-07-15
• First posted: 2024-10-08
• Last updated: 2024-10-08

Locations

1 site across 1 country: Egypt